Among the congenital disorders of blood clotting, Hageman factor deficiency (HF deficiency, Hageman trait), described by Ratnoff and Colopy in 1955,1 is unique: affected individuals have a profound abnormality of clotting, yet they are not bleeders. They come to the attention of a physician not because of a tendency to bleed or bruise excessively, but usually because a routine clotting time is fortuitously found to be prolonged. From this it is evident that HF is not essential for normal hemostasis, although it is essential for the normal clotting of blood in a test tube.
The role of HF in blood clotting may be demonstrated in the following manner. Normal plasma exposed to glass markedly accelerates the clotting of normal "intact" plasma, i.e. plasma not previously exposed to glass. This clot-accelerating activity generated in plasma by glass contact has been called Activation Product.2 Plasma from subjects with HF deficiency,
DIDISHEIM P. Hageman Factor Deficiency (Hageman Trait): Case Report and Review of the Literature. Arch Intern Med. 1962;110(2):170–177. doi:10.1001/archinte.1962.03620200030007
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: